ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 17, 2024 | $530,000 | Replaced |
| 3rd Quarter - Amendment | Mar 10, 2025 | $530,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
General Trade Issues. Drug Supply Chain.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| KATHERINE RAAB | — |
Pharmacy PHA
Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024. S.1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023. H.R.6109: Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act. Drug Shortages. S.2362 - Drug Shortage Prevention Act. S.2305: Biosimilar Red Tape Elimination Act. FDA Inspections. Drug-Device Combination Products. Third Party Drug Quality Studies. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KATHERINE RAAB | — |
Medicare/Medicaid MMM
Medicare Part D Reform. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023. H.R.1352/S.3934: Increasing Access to Biosimilars Act of 2023. Medicare Rebate Penalty.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KATHERINE RAAB | — |
Copyright/Patent/Trademark CPT
Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patent Eligibility Restoration Act. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.4878: The Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.8134: Restoring Americas Leadership In Innovation Act of 2024. H.R.9221/S.4840: Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KATHERINE RAAB | — |
Budget/Appropriations BUD
FDA Funding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KELBEL RAAB (NAME ERROR) | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.